The Oral Mesalazine Market plays an important role in the treatment of inflammatory bowel diseases (IBD), particularly ulcerative colitis and mild-to-moderate Crohn’s disease. Oral mesalazine, also known as mesalamine or 5-aminosalicylic acid (5-ASA), is widely prescribed to reduce intestinal inflammation, induce remission, and maintain long-term disease control. As the global burden of...